AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC) - Tolaney, SM; Chan, A; Petrakova, K (Ann Oncol, 2022)
et al.